Table of contents

Clinical/translational cancer immunotherapy

• Original research: First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors (31 October, 2022)

  Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C Cho, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Maria Vieito, Rowan E Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E Janik, Jason Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M Mehnert
• Original research: First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors (27 October, 2022)

  Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Jeffrey S Wasser, Eric Angevin, Patrick A Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B El-Khoueiry
• Original research: Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events (25 October, 2022)

  Alexander Coukos, Julien Vionnet, Michel Obeid, Hasna Bouchaab, Solange Peters, Sofiya Latifyan, Alexandre Wicky, Olivier Michielin, Haithem Chtioui, Darius Moradpour, François Fasquelle, Christine Sempoux, Montserrat Fraga
• Original research: Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO) (21 October, 2022)

  Marie Wislez, Julien Mazieres, Armelle Lavole, Gérard Zalcman, Olivier Carre, Thomas Egenod, Raffaele Caliandro, Catherine Dubos-Arvis, Gaelle Jeannin, Olivier Molinier, Marie-Ange Massiani, Alexandra Langlais, Franck Morin, Francoise Le Pimpec Barthes, Laurent Brouchet, Jalal Assouad, Bernard Milleron, Diane Damotte, Martine Antoine, Virginie Westeel
• Original research: Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions (19 October, 2022)

  Frank M Speetjens, Marij J P Welters, Marije Slingerland, Mariette I E van Poelgeest, Peggy J de Vos van Steenwijk, Inge Roozen, Sanne Boekestijn, Nikki M Loof, Gijs G Zom, A Rob P M Valentijn, Willem-Jan Krebber, Nico J Meeuwenoord, Catharina A H Janssen, Cornelis J M Melief, Gijs A van der Marel, Dmitri V Filippov, Sjoerd H van der Burg, Hans Gelderblom, Ferry Ossendorp
• Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis (17 October, 2022)

  Siqi Zhang, Mengge Zheng, Deheng Nie, Lili Xu, Huimin Tian, Mengmeng Wang, Wenjia Liu, Zhenbang Feng, Fujun Han
• Original research: Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer (17 October, 2022)

  Adrienne G Waks, Tanya E Keenan, Tianyu Li, Nabihah Tayob, Gerburg M Wulf, Edward T Richardson, Victoria Attaya, Leilani Anderson, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Ian E Krop, Judith Agudo, Eliezer M Van Allen, Sara M Tolaney
• Original research: Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors (12 October, 2022)

  Sven Borchmann, Carolin Selenz, Mia Lohmann, Hanna Ludwig, Asmae Gassa, Johannes Brägelmann, Philipp Lohneis, Lydia Meder, Julia Mattlener, Sara Breid, Marieke Nill, Jana Fassunke, Amy J. Wisdom, Anik Compes, Birgit Gathof, Hakan Alakus, David Kirsch, Khosro Hekmat, Reinhard Büttner, H. Christian Reinhardt, Michael Hallek, Roland T. Ullrich
• Original research: Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization (3 October, 2022)

  Justin C Jagodinsky, Amber M Bates, Paul A Clark, Raghava N Sriramaneni, Thomas C Havighurst, Ishan Chakravarty, Erin J Nystuen, KyungMann Kim, Paul M Sondel, Won Jong Jin, Zachary S Morris